Madrid, Spain and Heidelberg, Germany, April 22nd, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) will announce financial results for fiscal year 2014 and publish the Company’s Annual Report 2014 on April 29, 2015. On this occasion, the Company will host a conference call (conducted in English) at 15:00 Central European Time (CET) / 9:00 Eastern Time (ET) hosted by Pilar de la Huerta, CEO and CFO of SYGNIS to inform about the consolidated financial statements, important developments during the reporting period and provide a strategy update and financial outlook.
Conference Call details:
Date and time: April 29, 2015, 15:00 CET / 9:00 ET
Interested parties can access the conference call via the following telephone numbers:
• From Germany: +49 (0) 69 7104 45598
• From Spain: +34 91 787 0777
• From the US: +1 646 843 4608
•From the UK and other countries: +44 (0) 20 3003 2666
When prompted, you will be asked to give the password “SYGNIS”.
The conference call will be supplemented by a webcast presentation which can be accessed during the call under: www.meetingzone.com/presenter?partCEC=9269819.
Please dial in 5 minutes before the beginning of the event.
A conference call recording will be available in the “Investors” section of the Company’s website at www.sygnis.com.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi®, licensed to an industry leading partner and two own product lines on the market: TruePrime™ based on its proprietary TruePrime™ technology for whole genome amplification and SunScript™ Reverse Transcriptase to convert genetic information from RNA molecules back to DNA. Both product lines are addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications.
Help employers find you! Check out all the jobs and post your resume.
